<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004031</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065658</org_study_id>
    <secondary_id>S9704</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00004031</nct_id>
  </id_info>
  <brief_title>SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer
      cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of
      chemotherapy and radiation and kill more cancer cells. It is not yet known whether
      chemoradiotherapy plus peripheral stem cell transplantation is more effective than
      combination chemotherapy alone in treating non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying chemoradiotherapy and peripheral stem
      cell transplantation to see how well they work compared to combination chemotherapy in
      treating patients with stage II, stage III, or stage IV non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall survival and progression-free survival of patients with
           intermediate- or high-grade non-Hodgkin's lymphoma treated with high-dose
           chemoradiotherapy and autologous peripheral blood stem cell transplantation (APBSCT) vs
           conventional dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (or
           CHOP plus rituximab for CD20+ disease) with possible late APBSCT.

        -  Compare the toxic effects of these regimens in this patient population.

      OUTLINE: This is a randomized study. Patients are stratified according to disease risk
      (intermediate-high vs high).

      Patients receive CHOP chemotherapy comprising cyclophosphamide IV over 15 minutes,
      doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients with
      CD20-positive disease also receive rituximab IV on day 1 (or day 0 during course 1 only).
      Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or
      unacceptable toxicity.

      Within 35 days of completing the fifth course, patients with partial or complete response are
      randomized to one of two treatment arms.

        -  Arm I: Patients receive CHOP (or CHOP plus rituximab [CHOP-R]) as above. Treatment
           repeats every 3 weeks for 3 additional courses. After completion of chemotherapy,
           patients are encouraged to undergo harvest of peripheral blood stem cells (PBSC) for
           possible use at time of relapse. After completion of 8 courses, patients receive no
           additional therapy until disease progression or biopsy-proven disease.

        -  Arm II: Patients receive one additional course of CHOP/CHOP-R followed by filgrastim
           (G-CSF), sargramostim (GM-CSF), or other colony-stimulating factors used singly or in
           combination according to center preference. PBSC are harvested and selected for CD34+
           cells. Patients under age 61 receive one of two preparative regimens: a total body
           irradiation (TBI)-based regimen comprising irradiation administered twice daily on days
           -8 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on
           day -2 OR carmustine IV over 2 hours on days -6 to -4 and etoposide and cyclophosphamide
           as in the TBI-based regimen. Patients age 61 to 65 receive the augmented regimen
           comprising carmustine, etoposide, and cyclophosphamide as above. Patients receive
           involved field radiotherapy prior to the preparative regimen only if there is
           biopsy-proven residual bulk disease and at the discretion of the center. PBSC are
           reinfused 36-48 hours after completion of cyclophosphamide. If both bone marrow and PBSC
           are harvested, bone marrow is reinfused on day 0 and then PBSC are reinfused either the
           same day or the following day.

      Patients are followed every 6 months for 2 years and then annually thereafter.

      PROJECTED ACCRUAL: Approximately 360 patients (at least 135 per treatment arm) will be
      accrued for this study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>until death</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>until death</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">397</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 IV every 21 days</description>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 3</arm_group_label>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven intermediate- or high-grade non-Hodgkin's lymphoma

          -  Ann Arbor classification of &quot;bulky&quot; stage II, III, or IV

          -  Must be classified as high-intermediate or high-risk according to International Age
             Adjusted Index

          -  Bidimensionally measurable disease

          -  No lymphoblastic, transformed, or mantle cell lymphomas

          -  No CNS involvement by lymphoma

          -  CD20 status confirmed by immunocytochemistry or flow cytometry

          -  Must have either bilateral or unilateral bone marrow aspiration and biopsy ≥ 42 days
             before first course of cyclophosphamide, doxorubicin, vincristine, and prednisone
             (CHOP) therapy (or CHOP plus rituximab [CHOP-R] for CD20+ disease) OR within 42 days
             prior to registration if CHOP/CHOP-R therapy has not begun

          -  Must have bilateral bone marrow aspiration and biopsy within 28 days of randomization

               -  Bone marrow involvement with lymphoma is allowed, provided there is an
                  improvement of at least 50% if used as an evaluable site of disease

          -  No prior lymphoma, Hodgkin's lymphoma, myelodysplastic syndromes, or leukemia NOTE: A
             new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.
             The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former
             terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol
             uses the former terminology.

        PATIENT CHARACTERISTICS:

        Age:

          -  15 to 65

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  No nonlymphoma-related hepatic dysfunction

        Renal:

          -  Creatinine no greater than 2 times ULN

          -  Creatinine clearance at least 60 mL/min

          -  No nonlymphoma-related renal dysfunction

          -  No history of grade 3 hemorrhagic cystitis due to cyclophosphamide

        Cardiovascular:

          -  No coronary artery disease, cardiomyopathy, congestive heart failure, or dysrhythmia
             requiring therapy

          -  MUGA scan or 2-D echocardiogram required if patient's history is questionable

          -  Ejection fraction normal

        Pulmonary:

          -  DLCO or FEV_1 at least 60% of predicted

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other malignancy within the past 5 years except basal cell or squamous cell skin
             cancer or carcinoma in situ of the cervix

          -  No allergy to etoposide

          -  No active bacterial, fungal, or viral infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior monoclonal antibody therapy for lymphoma except if included in a single
             course of CHOP/CHOP-R

        Chemotherapy:

          -  No prior chemotherapy for lymphoma except for a single course of CHOP/CHOP-R* NOTE:
             *Prednisone or other corticosteroids not considered prior chemotherapy

        Endocrine therapy:

          -  See Chemotherapy

          -  Prior corticosteroids allowed

        Radiotherapy:

          -  No prior radiotherapy for lymphoma

          -  No prior thoracic radiotherapy or radiotherapy greater than 2,000 cGy to any other
             site

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick J. Stiff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas C. Shea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David P. Schenkein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tufts Medical Center Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Couban, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Care Nova Scotia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute at University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrement - Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Stiff PJ, Unger JM, Cook J, et al.: Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). [Abstract] J Clin Oncol 29 (Suppl 15): A-8001, 2011.</citation>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

